These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 26575250)

  • 1. Effect of canagliflozin on liver function tests in patients with type 2 diabetes.
    Leiter LA; Forst T; Polidori D; Balis DA; Xie J; Sha S
    Diabetes Metab; 2016 Feb; 42(1):25-32. PubMed ID: 26575250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
    Schernthaner G; Lavalle-González FJ; Davidson JA; Jodon H; Vijapurkar U; Qiu R; Canovatchel W
    Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
    Garcia de Lucas MD; Pérez Belmonte LM; Suárez Tembra M; Olalla Sierra J; Gómez Huelgas R
    Diabetes Metab; 2018 Sep; 44(4):373-375. PubMed ID: 29859992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
    Seko Y; Sumida Y; Sasaki K; Itoh Y; Iijima H; Hashimoto T; Ishii S; Inagaki N
    J Gastroenterol; 2018 Jan; 53(1):140-151. PubMed ID: 28669071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
    Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
    Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.
    Merton K; Davies MJ; Vijapurkar U; Inman D; Meininger G
    Curr Med Res Opin; 2018 Feb; 34(2):313-318. PubMed ID: 29022746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
    Lavalle-González FJ; Eliaschewitz FG; Cerdas S; Chacon Mdel P; Tong C; Alba M
    Curr Med Res Opin; 2016; 32(3):427-39. PubMed ID: 26579834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
    Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus.
    Wilding JP; Blonde L; Leiter LA; Cerdas S; Tong C; Yee J; Meininger G
    J Diabetes Complications; 2015 Apr; 29(3):438-44. PubMed ID: 25660137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
    Yale JF; Xie J; Sherman SE; Garceau C
    Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
    Blonde L; Stenlöf K; Fung A; Xie J; Canovatchel W; Meininger G
    Postgrad Med; 2016 May; 128(4):371-80. PubMed ID: 27002421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
    Cefalu WT; Stenlöf K; Leiter LA; Wilding JP; Blonde L; Polidori D; Xie J; Sullivan D; Usiskin K; Canovatchel W; Meininger G
    Diabetologia; 2015 Jun; 58(6):1183-7. PubMed ID: 25813214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
    Wilding JP; Charpentier G; Hollander P; González-Gálvez G; Mathieu C; Vercruysse F; Usiskin K; Law G; Black S; Canovatchel W; Meininger G
    Int J Clin Pract; 2013 Dec; 67(12):1267-82. PubMed ID: 24118688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates.
    John M; Cerdas S; Violante R; Deerochanawong C; Hassanein M; Slee A; Canovatchel W; Hamilton G
    Int J Clin Pract; 2016 Sep; 70(9):775-85. PubMed ID: 27600862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.
    Inagaki N; Harashima S; Maruyama N; Kawaguchi Y; Goda M; Iijima H
    Cardiovasc Diabetol; 2016 Jun; 15():89. PubMed ID: 27316668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
    Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
    Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
    Bode B; Stenlöf K; Harris S; Sullivan D; Fung A; Usiskin K; Meininger G
    Diabetes Obes Metab; 2015 Mar; 17(3):294-303. PubMed ID: 25495720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Stenlöf K; Cefalu WT; Kim KA; Alba M; Usiskin K; Tong C; Canovatchel W; Meininger G
    Diabetes Obes Metab; 2013 Apr; 15(4):372-82. PubMed ID: 23279307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.